Free Trial

Bicara Therapeutics (BCAX) Competitors

Bicara Therapeutics logo
$11.75 -0.18 (-1.51%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$11.74 -0.01 (-0.04%)
As of 07/25/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BCAX vs. RXRX, BHC, AGIO, ARWR, KNSA, TWST, CNTA, BEAM, CGON, and DNLI

Should you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Recursion Pharmaceuticals (RXRX), Bausch Health Cos (BHC), Agios Pharmaceuticals (AGIO), Arrowhead Pharmaceuticals (ARWR), Kiniksa Pharmaceuticals International (KNSA), Twist Bioscience (TWST), Centessa Pharmaceuticals (CNTA), Beam Therapeutics (BEAM), CG Oncology (CGON), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry.

Bicara Therapeutics vs. Its Competitors

Bicara Therapeutics (NASDAQ:BCAX) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Bicara Therapeutics currently has a consensus price target of $31.86, suggesting a potential upside of 171.14%. Recursion Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 7.86%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Bicara Therapeutics is more favorable than Recursion Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicara Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00
Recursion Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Recursion Pharmaceuticals had 12 more articles in the media than Bicara Therapeutics. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 1 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.82 beat Recursion Pharmaceuticals' score of 0.45 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Bicara Therapeutics Very Positive
Recursion Pharmaceuticals Neutral

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 15.5% of Bicara Therapeutics shares are owned by insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Bicara Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -961.32%. Bicara Therapeutics' return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Bicara TherapeuticsN/A N/A N/A
Recursion Pharmaceuticals -961.32%-74.70%-54.02%

Bicara Therapeutics has higher earnings, but lower revenue than Recursion Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bicara TherapeuticsN/AN/A-$68MN/AN/A
Recursion Pharmaceuticals$59.82M44.11-$463.66M-$1.77-3.67

Summary

Bicara Therapeutics beats Recursion Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Get Bicara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCAX vs. The Competition

MetricBicara TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$650.61M$3.05B$5.70B$9.50B
Dividend YieldN/A2.37%4.58%4.00%
P/E RatioN/A21.3228.3920.07
Price / SalesN/A270.06427.4498.54
Price / CashN/A42.7636.2258.56
Price / Book1.308.378.675.88
Net Income-$68M-$55.19M$3.25B$258.89M
7 Day Performance7.50%5.86%4.30%3.70%
1 Month Performance33.37%17.29%10.57%11.71%
1 Year PerformanceN/A4.39%35.68%17.98%

Bicara Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCAX
Bicara Therapeutics
2.0858 of 5 stars
$11.75
-1.5%
$31.86
+171.1%
N/A$650.61MN/A0.0032
RXRX
Recursion Pharmaceuticals
0.7817 of 5 stars
$6.40
+9.6%
$7.00
+9.4%
-19.4%$2.37B$58.84M-3.62400High Trading Volume
BHC
Bausch Health Cos
3.0919 of 5 stars
$6.34
+0.4%
$7.30
+15.2%
+15.1%$2.34B$9.63B-57.6020,700News Coverage
Upcoming Earnings
AGIO
Agios Pharmaceuticals
4.354 of 5 stars
$39.92
-0.2%
$58.60
+46.8%
-17.5%$2.32B$36.50M3.55390Upcoming Earnings
Analyst Forecast
ARWR
Arrowhead Pharmaceuticals
3.7806 of 5 stars
$14.71
-12.2%
$43.71
+197.2%
-45.6%$2.31B$3.55M-10.51400News Coverage
Positive News
High Trading Volume
KNSA
Kiniksa Pharmaceuticals International
3.4549 of 5 stars
$28.42
-2.1%
$39.67
+39.6%
+1.6%$2.12B$423.24M-113.68220News Coverage
TWST
Twist Bioscience
4.3618 of 5 stars
$34.77
-1.1%
$50.40
+45.0%
-37.4%$2.11B$312.97M-10.70990News Coverage
CNTA
Centessa Pharmaceuticals
3.3124 of 5 stars
$16.06
+2.4%
$28.10
+75.0%
+49.8%$2.10B$6.85M-8.87200News Coverage
Insider Trade
BEAM
Beam Therapeutics
2.259 of 5 stars
$21.03
+1.3%
$48.75
+131.8%
-32.5%$2.09B$63.52M-4.56510Analyst Revision
CGON
CG Oncology
2.6012 of 5 stars
$26.90
+0.6%
$55.30
+105.6%
-20.9%$2.04B$1.14M-17.8161Positive News
DNLI
Denali Therapeutics
4.2613 of 5 stars
$13.83
-1.2%
$33.71
+143.8%
-43.3%$2.03BN/A-5.18430News Coverage
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:BCAX) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners